Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > government financing I see GREEN
View:
Post by biggdogg on Nov 29, 2022 1:28pm

government financing I see GREEN

from powerplay interview, they are applying for grants and debt from government, with carbon neutral, this is highly probable. The sellers are not too bright. With gov funding any additional funding will be easily aquired. They are marketing their brand now, it will not be too long before they have first sale. I would suspect that Alberta government is going to buy this product to suppoert a local produced contrast drug. And get their plant built to create jobs and diversify the AB economy. All looks great. Keep dumping shares, I am sure there is a small financing coming to take them over the hump, only a few will get in on this next deal. Debt financing is coming, the green component ensures this.
Comment by lscfa on Nov 29, 2022 1:41pm
The feds just invested $27 million into E3, an pre-revenue Alberta lithium producer. VM's project  requires more effort to convince the feds to invest compared to the lithium EV battery space which is a hot topic.   https://www.canada.ca/en/innovation-science-economic-development/news/2022/11/government-of-canada-invests-in-e3-lithium-to-advance-canadas-ev-battery-production ...more  
Comment by biggdogg on Nov 29, 2022 2:59pm
I disagree, Voyageur is far ahead of E3, they are TRYING to get to a carbon neutral platform, they are chasing low grade lithium which is marginally economic. Voyageur has achieved this with the stroke of a pen by employing their fullerene partners technology. Voyageur will be the first truly carbon neutral company in Canada. This is a politicians dream project, carbon neutral, strategic ...more  
Comment by postie1 on Nov 29, 2022 3:13pm
biggdogg, That  post deserves 3 thumbs up imo.  Let us hope the gov't reads it.
Comment by CheckingReality on Nov 29, 2022 8:49pm
This is one of the most positive posts about Voyageur and the potential of their projects. Far too many posts slam the company without seeing the potential. Time will tell. GTLA
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1